Enlivex Therapeutics Ltd. (ENLV) Balance Sheet
ENLV balance sheet, 2025
December 31, 2025 · U.S. dollars$2.33B assets = $392.1M liabilities + $1.93B equity
Both columns are drawn to the same scale: what ENLV owns equals what it owes plus shareholders’ equity. Hover a block for its value.
ENLV financial health
Descriptive bands, not a rating. Fiscal 2025.
ENLV balance sheet trends, 2016–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $10.6M2016 | $2.33B2025 | +82.0%/yr | |
| Total liabilities | $1.9M2016 | $392.1M2025 | +80.5%/yr | |
| Shareholders’ equity | $8.7M2016 | $1.93B2025 | +82.3%/yr | |
| Cash & short-term investments | $9.9M2016 | $5.9M2025 | −5.6%/yr | |
| Total debt | $123,0002019 | $641,0002025 | +31.7%/yr | |
| Net cash (debt) | $11.9M2019 | $5.2M2025 | −$6.7M | |
| Working capital | $8.6M2016 | $1.73B2025 | +$1.7B | |
| Debt / equity | 0.012019 | 0.002025 | −0.01 |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
ENLV assets
ENLV liabilities and equity
ENLV debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
ENLV balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & short-term investments | $5.9M | $23.6M | $27.3M | $50.2M | $84.1M | $35.7M | $12.0M | $9.8M | $3.5M | $9.9M |
| Cash & equivalents | $2.0M | $3.3M | $813,000 | $49.9M | $11.2M | $5.7M | $3.9M | $9.7M | $3.5M | $6.9M |
| Short-term investments | $3.9M | $20.2M | $26.5M | $299,000 | $72.9M | $30.0M | $8.1M | $40,000 | — | $3.0M |
| Receivables | $235,000 | $1.3M | $229,000 | $647,000 | $1.1M | $1.2M | $2.4M | $213,000 | $28,000 | $52,000 |
| Inventory | $0 | $0 | −$229,000 | $1.2M | −$12.2M | −$31.2M | $1.5M | $0 | $0 | $0 |
| Other current assets | $1.74B | $1.1M | $6.4M | $262,000 | $13.4M | $32.4M | $510,000 | $288,000 | $68,000 | $611,000 |
| Total current assets | $1.74B | $26.0M | $33.8M | $52.3M | $86.4M | $38.1M | $16.4M | $10.3M | $3.6M | $10.5M |
| Property, plant & equipment (net) | $938,000 | $1.2M | $2.6M | $14.9M | $8.2M | $2.1M | $1.1M | $685,000 | $388 | $71,000 |
| Goodwill & intangible assets | $582.5M | $0 | $0 | $0 | $0 | $0 | $410,000 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $3,000 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $374,000 | $541,000 | $487,000 | $412,000 | $482,000 | $97,000 | $0 | $72,000 | $0 | $18,000 |
| Total assets | $2.33B | $27.7M | $36.8M | $67.6M | $95.1M | $40.4M | $17.6M | $11.0M | $3.6M | $10.6M |
| Liabilities | ||||||||||
| Accounts payable | $3.8M | $811,000 | $827,000 | $1.9M | $878,000 | $463,000 | $316,000 | $173,000 | $19,000 | $32,000 |
| Short-term debt | $258,000 | $235,000 | $346,000 | $653,000 | $617,000 | $203,000 | $123,000 | — | — | — |
| Total current liabilities | $9.0M | $3.8M | $6.1M | $6.6M | $4.7M | $4.4M | $6.0M | $1.1M | $460,000 | $1.9M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | $641,000 | $534,000 | $1.0M | $653,000 | $617,000 | $203,000 | $123,000 | — | — | — |
| Other long-term liabilities | $383.0M | $299,000 | $686,000 | $4.2M | $5.4M | $499,000 | $298,000 | $198,000 | $7,000 | $6,000 |
| Total liabilities | $392.1M | $4.1M | $6.7M | $10.8M | $10.1M | $4.9M | $6.3M | $1.3M | $460,000 | $1.9M |
| Shareholders' equity | ||||||||||
| Common stock & paid-in capital | $28.7M | $2.7M | $2.1M | $2.1M | $2.1M | $1.6M | $1.2M | $396,000 | $45,000 | $45,000 |
| Retained earnings (deficit) | $1.11B | −$127.1M | −$112.1M | −$83.0M | −$52.0M | −$37.5M | −$25.7M | −$16.3M | −$45.8M | −$39.8M |
| Accumulated other comprehensive income | $1.1M | $1.1M | $1.1M | $1.1M | $1.1M | $977,000 | −$1.3M | −$2.3M | −$1,502 | −$40,000 |
| Total shareholders' equity | $1.93B | $23.6M | $30.1M | $56.8M | $85.0M | $35.5M | $11.3M | $9.7M | $3.2M | $8.7M |
| Key figures | ||||||||||
| Total debt | $641,000 | $534,000 | $1.0M | $4.8M | $6.0M | $203,000 | $123,000 | — | — | — |
| Net cash (debt) | $5.2M | $23.1M | $26.3M | $45.4M | $78.1M | $35.5M | $11.9M | — | — | — |
| Working capital | $1.73B | $22.2M | $27.7M | $45.7M | $81.7M | $33.7M | $10.4M | $9.1M | $3.2M | $8.6M |
| Tangible book value | $1.35B | $23.6M | $30.1M | $56.8M | $85.0M | $35.5M | $10.9M | $9.7M | $3.2M | $8.7M |
| Current ratio | 193.24 | 6.84 | 5.57 | 7.92 | 18.32 | 8.72 | 2.75 | 9.09 | 7.87 | 5.46 |
| Quick ratio | 0.68 | 6.56 | 4.55 | 7.70 | 18.06 | 8.45 | 2.41 | 8.84 | 7.73 | 5.14 |
| Debt / equity | 0.00 | 0.02 | 0.03 | 0.09 | 0.07 | 0.01 | 0.01 | — | — | — |
| Equity / assets | 83.2% | 85.2% | 81.7% | 84.0% | 89.4% | 87.9% | 64.2% | 88.0% | 87.3% | 81.8% |
| Jun '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & short-term investments | $5.5M | $5.9M | $18.3M | $19.5M | $20.6M | $23.6M | $24.5M | $25.9M | $23.5M | $27.4M | $30.5M |
| Cash & equivalents | $5.5M | $2.0M | $4.2M | $1.9M | $2.1M | $3.3M | $2.8M | $3.7M | $2.0M | $926,000 | $2.0M |
| Short-term investments | — | $3.9M | $14.1M | $17.6M | $18.5M | $20.2M | $21.7M | $22.2M | $21.5M | $26.5M | $28.5M |
| Receivables | $25,000 | $235,000 | $567,000 | $890,000 | $1.1M | $1.3M | $1.3M | $1.1M | $3.7M | $229,000 | $1.3M |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $113,000 | $113,000 | −$229,000 | −$229,000 | −$1.2M |
| Other current assets | $3.75B | $1.74B | $615,000 | $927,000 | $963,000 | $1.1M | $1.2M | $1.4M | $1.4M | $6.3M | $1.2M |
| Total current assets | $3.75B | $1.74B | $19.5M | $21.3M | $22.6M | $26.0M | $27.1M | $28.6M | $28.4M | $33.8M | $31.8M |
| Property, plant & equipment (net) | $249,000 | $938,000 | $1.1M | $923,000 | $1.1M | $1.2M | $1.8M | $2.0M | $2.2M | $2.6M | $14.3M |
| Goodwill & intangible assets | $1.15B | $582.5M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $1.9M | $374,000 | $359,000 | $351,000 | $319,000 | $541,000 | $915,000 | $1.3M | $429,000 | $487,000 | $796,000 |
| Total assets | $4.90B | $2.33B | $20.9M | $22.6M | $24.0M | $27.7M | $29.8M | $31.9M | $31.0M | $36.8M | $46.9M |
| Liabilities | |||||||||||
| Accounts payable | $1.7M | $3.8M | $375,000 | $542,000 | $533,000 | $811,000 | $92,000 | $303,000 | $643,000 | $827,000 | $794,000 |
| Short-term debt | $16.9M | $258,000 | $275,000 | $264,000 | $239,000 | $235,000 | $346,000 | $336,000 | $341,000 | $346,000 | $701,000 |
| Total current liabilities | $31.4M | $9.0M | $3.0M | $3.3M | $3.1M | $3.8M | $2.8M | $2.8M | $3.6M | $6.1M | $4.3M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | — | $641,000 | $701,000 | $480,000 | $503,000 | $534,000 | $765,000 | $835,000 | $928,000 | $1.0M | $4.5M |
| Other long-term liabilities | $970.3M | $383.0M | $425,999 | $216,000 | $264,000 | $299,000 | $419,000 | $499,000 | $587,000 | $686,000 | $3.8M |
| Total liabilities | $1.00B | $392.1M | $3.5M | $3.5M | $3.4M | $4.1M | $3.2M | $3.3M | $4.2M | $6.7M | $8.2M |
| Shareholders' equity | |||||||||||
| Common stock & paid-in capital | $30.7M | $28.7M | $2.8M | $2.7M | $2.7M | $2.7M | $2.5M | $2.4M | $2.2M | $2.1M | $2.1M |
| Retained earnings (deficit) | $3.06B | $1.11B | −$134.6M | −$132.4M | −$130.6M | −$127.1M | −$121.9M | −$119.3M | −$116.2M | −$112.1M | −$103.0M |
| Accumulated other comprehensive income | $1.1M | $1.1M | $1.1M | $1.1M | $1.1M | $1.1M | $1.1M | $1.1M | $1.1M | $1.1M | $1.1M |
| Total shareholders' equity | $3.90B | $1.93B | $17.5M | $19.1M | $20.6M | $23.6M | $26.6M | $28.6M | $26.9M | $30.1M | $38.8M |
| Key figures | |||||||||||
| Total debt | $17.2M | $641,000 | $701,000 | $480,000 | $503,000 | $534,000 | $765,000 | $835,000 | $928,000 | $1.0M | $4.5M |
| Net cash (debt) | −$11.7M | $5.2M | $17.6M | $19.0M | $20.0M | $23.1M | $23.7M | $25.1M | $22.6M | $26.4M | $26.0M |
| Working capital | $3.72B | $1.73B | $16.5M | $18.0M | $19.5M | $22.2M | $24.3M | $25.7M | $24.8M | $27.7M | $27.5M |
| Tangible book value | $2.75B | $1.35B | $17.5M | $19.1M | $20.6M | $23.6M | $26.6M | $28.6M | $26.9M | $30.1M | $38.8M |
| Book value per share | $201.63 | — | — | — | — | — | — | — | — | $1.62 | — |
| Shares outstanding | 19.3M | — | — | — | — | — | — | — | — | 18.6M | — |
| Current ratio | 119.39 | 193.24 | 6.43 | 6.41 | 7.20 | 6.84 | 9.71 | 10.06 | 7.86 | 5.57 | 7.34 |
| Quick ratio | 0.18 | 0.68 | 6.23 | 6.13 | 6.90 | 6.56 | 9.24 | 9.53 | 7.55 | 4.56 | 7.34 |
| Debt / equity | 0.00 | 0.00 | 0.04 | 0.03 | 0.02 | 0.02 | 0.03 | 0.03 | 0.03 | 0.03 | 0.12 |
| Equity / assets | 79.6% | 83.2% | 83.5% | 84.3% | 85.8% | 85.2% | 89.2% | 89.5% | 86.5% | 81.7% | 82.6% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 25, 2026); data from EODHD.
ENLV financial position
At the end of fiscal 2025 (December 31, 2025), Enlivex Therapeutics had total assets of $2.3 billion (up 8,304.7% from a year earlier), total liabilities of $392.1 million and shareholders' equity of $1.9 billion. It held $5.9 million in cash and short-term investments against $0.6 million of debt, a net cash position of $5.2 million. Its current ratio was 193.24. In the latest quarter (ended June 30, 2026) total assets were $4.9 billion and equity $3.9 billion.
Related: ENLV income statement, ENLV cash flow statement, ENLV key metrics. See the ENLV stock overview for the latest quote and news.
ENLV balance sheet FAQ
What are Enlivex Therapeutics's total assets?
Enlivex Therapeutics reported total assets of $2.3 billion at the end of fiscal 2025 (December 31, 2025), compared with $27.7 million a year earlier.
How much debt does Enlivex Therapeutics have?
Enlivex Therapeutics had $0.6 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.00.
How much cash does Enlivex Therapeutics have?
Enlivex Therapeutics held $5.9 million in cash and short-term investments at the end of fiscal 2025; with $0.6 million of debt that is net cash of $5.2 million.
What is Enlivex Therapeutics's book value?
Enlivex Therapeutics's shareholders' equity (book value) was $1.9 billion at the end of fiscal 2025.
What is Enlivex Therapeutics's current ratio?
Enlivex Therapeutics had current assets of $1.7 billion and current liabilities of $9.0 million, a current ratio of 193.24 (it can cover its short-term obligations).
How much goodwill does Enlivex Therapeutics have?
Enlivex Therapeutics carried $582.5 million of goodwill and intangible assets, 25.0% of total assets, at the end of fiscal 2025.